Pharmadrug (TSE:PHRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaDrug’s Sairiyo Therapeutics has successfully completed a stability study of its reformulated cepharanthine, PD-001, paving the way for its Phase 1 clinical trial as a potential treatment for viral infectious diseases. This development marks a significant step forward in leveraging cepharanthine’s improved oral bioavailability for more effective therapeutic applications. The completion of the study allows the company to proceed with manufacturing and clinical trial preparations in Australia.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts